Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis
Antimicrobial Agents and Chemotherapy · 2024
DOI: 10.1128/aac.00595-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2024. Verfasst von Henry S Heine und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Florida, Orlando, Florida, USA. Hauptthemen laut MEDLINE: Ciprofloxacin, Bacillus anthracis, Microbial Sensitivity Tests, Anthrax. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Bacillus anthracis , the causative agent of anthrax, is among the most likely bacterial pathogens to be used in a biological attack. Inhalation anthrax is a serious, life-threatening form of infection, and the mortality from acute inhaled anthrax can approach 100% if not treated early and aggressively. Food and Drug Administration-approved antibiotics indicated for post-exposure prophylaxis (PEP) or treatment of anthrax are limited. This study assessed the in vitro activity and in vivo efficacy of omadacycline and comparators against clinical isolates of B. anthracis, including a ciprofloxacin-resistant isolate. Minimum inhibitory concentrations (MICs) of omadacycline, ciprofloxacin, and doxycycline were determined against animal and human clinical isolates of B. anthracis , including the ciprofloxacin-resistant Ames strain BAC r 4-2. Mice were challenged with aerosolized BAC r 4-2 spores, and survival was monitored for 28 days post-challenge. Treatment was initiated 24 h after aerosol challenge and administered for 14 days. Omadacycline demonstrated in vitro activity against 53 B. anthracis isolates with an MIC range of ≤0.008–0.25 µg/mL, and an MIC 50 /MIC 90 of 0.015/0.03 µg/mL. Consistent with this, omadacycline demonstrated in vivo efficacy in a PEP mouse model of inhalation anthrax caused by the Ames BAC r 4-2 ciprofloxacin-resistant B. anthracis isolate. Omadacycline treatment significantly increased survival compared with the vehicle control group and the ciprofloxacin treatment group. As antibiotic resistance rates continue to rise worldwide, omadacycline may offer an alternative PEP or treatment option against inhalation anthrax, including anthrax caused by antibiotic-resistant B. anthracis .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Florida, Orlando, Florida, USA.
- Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
ORCID-Profile: Henry S Heine, George Drusano, Alisa W Serio
Zitieren
APA
Heine, H. S., Drusano, G., Purcell, B. K., Anastasiou, D., Tanaka, S. K., & Serio, A. W. (2024). Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00595-24
Vancouver
Heine HS, Drusano G, Purcell BK, Anastasiou D, Tanaka SK, Serio AW. Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis. Antimicrobial Agents and Chemotherapy. 2024. doi:10.1128/aac.00595-24
BibTeX
@article{Heine2024,
author = {Heine, Henry S and Drusano, George and Purcell, Bret K and Anastasiou, Diane and Tanaka, S Ken and Serio, Alisa W},
title = {Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2024},
doi = {10.1128/aac.00595-24}
}
EUVIMED